Oct 14, 2026 08:00AM
Aug 24, 2026 08:39AM
Aug 5, 2026 04:50PM
Jul 14, 2026 11:39AM
Jul 13, 2026 10:38PM
Jul 13, 2026 10:37PM
Jul 13, 2026 12:02AM New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease
Jun 30, 2026 02:44AM
Jun 16, 2026 08:00AM
Jun 16, 2026 08:00AM
May 25, 2026 03:33AM
May 15, 2026 02:55AM
May 8, 2026 09:00AM
May 8, 2026 02:48AM FDA extends Leqembi Iqlik review period to August 24
May 8, 2026 02:48AM
May 8, 2026 02:47AM
Apr 21, 2026 07:01AM
Apr 21, 2026 07:00AM
Mar 24, 2026 09:00AM
Mar 23, 2026 03:50AM
Feb 6, 2026 06:17AM Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
Jan 21, 2026 10:30PM
Jan 21, 2026 10:30PM
Jan 20, 2026 04:01PM
Jan 20, 2026 04:01PM
Jan 20, 2026 09:01AM
Jan 20, 2026 09:00AM
Jan 12, 2026 09:01AM BioAge reports 86% reduction in inflammatory marker in Phase 1 trial
Jan 12, 2026 09:00AM
Dec 8, 2025 06:42PM
Dec 4, 2025 09:01AM
Dec 4, 2025 09:00AM
Dec 4, 2025 02:13AM
Nov 18, 2025 07:02PM
Nov 13, 2025 06:50PM Leqembi® approved for IV maintenance treatment in the United Kingdom
Nov 6, 2025 04:45PM
Oct 26, 2025 10:56PM
Sep 2, 2025 11:01PM
Aug 25, 2025 03:26AM
Aug 15, 2025 09:00AM
Aug 15, 2025 09:00AM
Aug 6, 2025 04:30PM BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates
Jul 30, 2025 10:54PM
Jun 21, 2025 06:00PM
Jun 17, 2025 09:08AM
Jun 17, 2025 09:00AM
Jun 3, 2025 09:00AM
May 29, 2025 09:00AM
May 29, 2025 09:00AM BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic
May 15, 2025 04:56AM

334,273 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All